Overview

A Phase I/II Clinical Study in Patients With Advanced Solid Tumor.

Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
This is a 2-part, phase I/II, open-label, multicenter study designed to evaluate the safety, PK, PD and preliminary efficacy of TCC1727 tablets administered orally QD.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beijing Tide Pharmaceutical Co., Ltd